2020 Guide to Patient Support Services

Pfizer Oncology

Pfizer Oncology Together is a patient support program that provides patients and providers access to reimbursement services, financial assistance services, and personalized patient support offerings. Patients may be eligible for different support service options based on their needs and on the Pfizer oncology medication they are prescribed.

The complete list of Pfizer oncology and oncology supportive care drugs and their indications and support programs is provided in the Table.

PFIZER ONCOLOGY TOGETHER

Patients with commercial insurance and prescription coverage who need assistance obtaining certain Pfizer medications may be eligible for one of the Pfizer Oncology Together programs. Patients who are prescribed Bosulif (bosutinib), Daurismo (glasdegib), Ibrance (palbociclib), Inlyta (axitinib), Lorbrena (lorlatinib), Nivestym (filgrastim-aafi), Retacrit (epoetin alfa-epbx), Sutent (suniti­nib malate), Talzenna (talazoparib), Vizimpro (dacomitinib), or Xalkori (crizotinib) may be eligible for the Pfizer Co-Pay Savings Program.

Patients who are prescribed Aromasin (exemestane) may be eligible for the Aromasin Savings Card.

Pfizer Oncology Together offers patients assistance with handling their benefits verification, prior authorization and appeals, and specialty pharmacy coordination.

For patients with Medicare coverage, including Part D, Medicaid, or other government insurance plans, Pfizer Oncology Together helps to identify financial support resources from independent charitable foundations. These foundations have their own eligibility criteria and application process, and availability of support is determined solely by the foundations.

The Pfizer Patient Assistance Program may be able to help patients to receive free medicine if independent charitable foundations are not available. Patients may also receive assistance in finding alternate insurance options. Eligible patients may receive up to a 90-day supply of the medicine until alternative options become available. Patients who are unable to secure insurance coverage may be eligible to receive their medication for free for up to 12 months.

For uninsured patients, Pfizer Oncology Together will help to determine patients’ eligibility for Medicaid or Medicare’s Low Income Subsidy, and will provide assistance with the application process.

Regardless of coverage status, the Free Trial Voucher program offers newly diagnosed patients who are prescribed Bosulif, Ibrance, Inlyta, or Sutent a free trial voucher, which they may get from their healthcare provider. The duration of the free trial is drug-specific (eg, Sutent, 28 days; Inlyta, 30 days; Bosulif, 30 days).

ELIGIBILITY

Pfizer Co-Pay Savings Program

Patients enrolled in this program will pay as little as a $0 copay monthly for certain Pfizer medications, with a maximum savings of $25,000 annually. The copay savings card may be used once in 30 days until the maximum benefit has been reached. To be eligible for this program, patients must:

  • Have commercial insurance
  • Be aged >18 years
  • Reside in the United States or Puerto Rico.

The savings card is only accepted at participating pharmacies. This program is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare, TRICARE, or other federal- or state-funded healthcare programs, or by private insurance plans or other health or pharmacy benefit programs. Click here for more information.

Pfizer Oncology Together IV Co-Pay Program

This program provides assistance for eligible, commercially insured patients for copays, coinsurance, or deductibles incurred for intravenous medications, up to drug-specific $10,000 or $25,000 annually. Patients may pay as little as a $0 copay for their medication, but once their annual limit is reached, they are responsible for paying their copay in full.

To be eligible for this program, patients must:

  • Be aged >18 years
  • Have commercial insurance that covers the medication
  • Not be enrolled in a federal- or state-funded insurance program
  • Reside in the United States or Puerto Rico.

This program has no income requirements.

Aromasin Savings Card

Patients enrolled in this program may pay as little as $4 for a 30-day fill and have a maximum monthly savings of $300, and an annual maximum savings of $3600. To be eligible for the program, patients must:

  • Be aged >18 years and reside in the United States or Puerto Rico
  • Have commercial insurance
  • Have prescriptions that are not eligible to be reimbursed by federal- or state-funded programs, private insurance plans, or other health or pharmacy benefit programs.

Pfizer Patient Assistance Program

To qualify for enrollment in this program, patients must:

  • Have been prescribed a Pfizer Group B medicine by a qualified US physician
  • Reside in the United States, Puerto Rico, or the US Virgin Islands
  • Have no prescription drug coverage, or not enough coverage to afford a Pfizer medication
  • Meet income requirements that vary by medicine and by household size.

APPLICATION & ENROLLMENT

Pfizer Oncology Together

To enroll in this program, patients must complete an enrollment form, and fax it to 877-736-6506.

Pfizer Co-Pay Savings Program

To enroll in this program and receive a co-pay savings card, patients must complete a drug-specific enrollment form.

Pfizer Oncology Together IV Co-Pay Program

To enroll in this program, patients or their providers must submit a Pfizer Oncology Together enrollment form. On approval of the patient’s eligibility, the patient and the provider will receive approval letters with the IV Co-Pay Program group number and patient’s IV Co-Pay Program identification number, which are required for the submission of claims. Enrollment does not guarantee copay assistance. Eligibility for a copay expense for the IV Co-Pay Program benefit will be determined at the time the benefit is paid.

Aromasin Savings Card

The Aromasin Savings Card may be requested by completing a form online, or by calling 866-562-6151.

Pfizer Patient Assistance Program

To enroll in this program, the prescriber must fax the completed application to 800-708-3430 or mail it to the address on the form, along with any other required documents.

Several documents must be submitted for income verification, including the previous year’s federal tax returns; paycheck stubs; wage and tax statements; Social Security, pension, or railroad retirement statements; and statements of interest, dividends, or other income.

After applying to this program, counselors will help patients identify and apply for alternate programs that can facilitate access to their medicine. These may be state drug assistance programs, copay foundations, or Medicare’s Low Income Subsidy. For information on participating pharmacies, call 866-706-2400.

ADDITIONAL SERVICES

In 2017, Pfizer launched its new program, This Is Living With Cancer, which features the free mobile app LivingWith—designed to help patients to manage their lives with cancer. This program provides tools and resources to connect patients with their loved ones, provides help with daily living tasks, and improves communication with healthcare providers. This app also serves as a way to stay organized and keep track of questions and notes for physicians, reminders, and paperwork.

TABLE PFIZER ONCOLOGY/SUPPORTIVE CARE DRUGS

Drugs
Indications
Patient support programs

Drug
Aromasin (exemestane) tablets
Indications
ER-positive early breast cancer; advanced breast cancer that progressed with tamoxifen
Patient support programs

Drug
Besponsa (inotuzumab ozogamicin)
Indications
Relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Patient support program

Drug
Bosulif (bosutinib)
Indications
First-line treatment of Ph+ chronic myeloid leukemia (CML); relapsed or refractory chronic-, accelerated-, or blast-phase Ph+ CML
Patient support programs

Drug
Camptosar (irinotecan hydrochloride injection)
Indications
Metastatic colorectal cancer, alone or with 5-fluorouracil and leucovorin
Patient support program

Drug
Daurismo (glasdegib)
Indications
Newly diagnosed acute myeloid leukemia in adults aged ≥75 years or patients whose comorbidities preclude intensive chemotherapy induction, in combination with low-dose cytarabine
Patient support programs

Drug
Ellence (epirubicin hydrochloride injection)
Indications
Breast cancer adjuvant therapy in patients with evidence of axillary node tumor involvement after primary resection
Patient support program

Drug
Emcyt (estramustine phosphate sodium)
Indications
Metastatic and/or progressive prostate cancer
Patient support program

Drug
Ibrance (palbociclib)
Indications
HR-positive, HER2-negative advanced breast cancer
Patient support programs

Drug
Idamycin PFS (idarubicin hydrochloride)
Indications
Acute myeloid leukemia in adults, with other antileukemic drugs
Patient support program

Drug
Inlyta (axitinib)
Indications
Advanced renal-cell carcinoma, after failure of 1 systemic therapy
Patient support programs

Drug
Lorbrena (lorlatinib)
Indications
Metastatic NSCLC with ALK mutation progressing with crizotinib therapy and ≥1 other ALK inhibitors for metastatic disease; or after ceritinib or alectinib therapy as first ALK inhibitor for metastatic disease
Patient support programs

Drug
Nivestym (filgrastim-aafi) injection
Indications
Patient support programs

Drug
Retacrit (epoetin alfa-epbx)
Indications
Treatment of anemia associated with concomitant myelosuppressive chemotherapy in patients with nonmyeloid malignancies
Patient support program

Drug
Sutent (sunitinib malate)
Indications
GIST; advanced renal-cell carcinoma; neuroendocrine tumors of pancreatic origin
Patient support programs

Drug
Talzenna (talazoparib)
Indications
HER2-negative locally advanced or metastatic breast cancer with BRCA mutations
Patient support programs

Drug
Torisel (temsirolimus)
Indications
Advanced renal-cell carcinoma
Patient support program

Drug
Vizimpro (dacomitinib)
Indications
First-line treatment of metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations
Patient support programs

Drug
Xalkori (crizotinib)
Indications
Metastatic NSCLC with ALK or ROS1 mutations
Patient support programs

Drug
Zinecard (dexrazoxane)
Indications
Reduce doxorubicin-induced cardiomyopathy in metastatic breast cancer
Patient support program

ALK indicates anaplastic lymphoma kinase; ER, estrogen receptor; GIST, gastrointestinal stromal tumor; HR, hormone receptor; NSCLC, non–small-cell lung cancer; Ph+, Philadelphia chromosome–positive.

Nivestym (filgrastim-aafi) injection Indications

To decrease infection (ie, febrile neutropenia) in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs; reduce time to neutrophil recovery and fever, after chemotherapy in patients with acute myeloid leukemia; reduce duration of neutropenia and neutropenia-related sequelae in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by transplant; for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis; to reduce incidence/duration of neutropenia sequelae in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: